First Analysis Comments on Charles River Laboratories Intl. Inc’s FY2017 Earnings (NYSE:CRL)

Charles River Laboratories Intl. Inc (NYSE:CRL) – Equities researchers at First Analysis raised their FY2017 EPS estimates for shares of Charles River Laboratories Intl. in a research report issued to clients and investors on Monday, Zacks Investment Research reports. First Analysis analyst T. Van. Fleet now anticipates that the medical research company will post earnings of $5.15 per share for the year, up from their previous estimate of $5.05. First Analysis also issued estimates for Charles River Laboratories Intl.’s Q4 2017 earnings at $1.26 EPS.

Several other equities analysts have also commented on the stock. Bank of America dropped their price target on shares of Charles River Laboratories Intl. from $117.00 to $115.00 and set a “buy” rating on the stock in a research note on Friday, November 10th. Argus started coverage on shares of Charles River Laboratories Intl. in a research note on Wednesday, December 13th. They issued a “buy” rating and a $120.00 price target on the stock. Zacks Investment Research upgraded shares of Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $129.00 target price on the stock in a research report on Tuesday, October 24th. ValuEngine lowered shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research report on Friday, November 10th. Finally, Royal Bank of Canada started coverage on shares of Charles River Laboratories Intl. in a research report on Tuesday, September 19th. They set a “sector perform” rating and a $110.00 target price on the stock. Six equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $112.36.

Shares of Charles River Laboratories Intl. (CRL) traded down $2.72 during trading on Wednesday, reaching $105.34. 694,058 shares of the company’s stock traded hands, compared to its average volume of 276,704. The stock has a market capitalization of $5,117.89, a price-to-earnings ratio of 25.69, a P/E/G ratio of 1.58 and a beta of 0.88. Charles River Laboratories Intl. has a one year low of $77.61 and a one year high of $119.05. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.88 and a quick ratio of 1.62.

Charles River Laboratories Intl. (NYSE:CRL) last announced its quarterly earnings results on Thursday, November 9th. The medical research company reported $1.30 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.22 by $0.08. The company had revenue of $464.23 million for the quarter, compared to analyst estimates of $458.93 million. Charles River Laboratories Intl. had a net margin of 10.72% and a return on equity of 26.58%. The firm’s revenue was up 9.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.18 earnings per share.

A number of large investors have recently bought and sold shares of the stock. Alps Advisors Inc. grew its position in Charles River Laboratories Intl. by 0.3% in the 2nd quarter. Alps Advisors Inc. now owns 5,350 shares of the medical research company’s stock valued at $541,000 after buying an additional 14 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in Charles River Laboratories Intl. by 0.5% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 6,953 shares of the medical research company’s stock valued at $703,000 after buying an additional 33 shares during the last quarter. M&T Bank Corp grew its position in Charles River Laboratories Intl. by 1.8% in the 2nd quarter. M&T Bank Corp now owns 4,358 shares of the medical research company’s stock valued at $441,000 after buying an additional 76 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. grew its position in Charles River Laboratories Intl. by 1.5% in the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 13,171 shares of the medical research company’s stock valued at $1,332,000 after buying an additional 200 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in Charles River Laboratories Intl. by 12.7% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock valued at $181,000 after buying an additional 202 shares during the last quarter. Hedge funds and other institutional investors own 95.80% of the company’s stock.

In related news, Director Robert J. Bertolini sold 3,609 shares of Charles River Laboratories Intl. stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $110.22, for a total value of $397,783.98. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Bradley Nixon Scharfe sold 1,000,000 shares of Charles River Laboratories Intl. stock in a transaction on Friday, November 10th. The shares were sold at an average price of $0.27, for a total transaction of $270,000.00. Over the last 90 days, insiders have bought 10,500 shares of company stock worth $2,885 and have sold 1,064,673 shares worth $2,876,056. Company insiders own 2.20% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “First Analysis Comments on Charles River Laboratories Intl. Inc’s FY2017 Earnings (NYSE:CRL)” was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://www.thelincolnianonline.com/2018/01/13/analysts-issue-forecasts-for-charles-river-laboratories-international-inc-s-fy2017-earnings-crl-updated-updated.html.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Get a free copy of the Zacks research report on Charles River Laboratories Intl. (CRL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply